Characterization of hematopoietic stem and progenitor cells

Williams, Douglas E.; Lü, Li; Broxmeyer, Hal E.

doi:10.1007/bf02935524

Cited by 18 publications

(6 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating blood cells are derived and replaced by the hemopoietic stem and progenitor cell pools (Williams et al, 1987). Hemopoietic progenitor cells are present in human adult bone marrow but also in adult peripheral blood and umbilical cord blood (Caracciola et al, 1989).…”

Section: Human Umbilical Cord Blood As a Source Of Hemopoietic Progenmentioning

confidence: 99%

Hemopoietic and Lymphoid Progenitor Cells in HumanUmbilical Cord Blood

Cicuttini

Boyd

1993

Journal of Immunology Research

View full text Add to dashboard Cite

Human umbilical cord blood, which in the past was discarded with the placental tissue, provides a convenient source of fetal hemopoietic cells for scientific analysis and clinical use. Cord blood cells are immature compared to analogous populations in adult peripheral blood. Cord blood B lymphocytes display unique phenotypic and functional characteristics. The antigens CD1C, CD38, CD5, and CD23, although normally expressed on only a small percentage of circulating B cells in adults, are highly expressed on cord blood B cells. Recent studies have demonstrated that whereas cord blood B cells are functionally naive, their potential is similar to that of adult B cells if optimal T-cell help is available. Thus, the failure of B-cell responses in cord blood is due to the T cells. The functional abnormalities of T cells from newborns can be summarized as a dominance of the effects of TH0 cells. Thus, the cytokines produced are immunosuppressive rather than mediating helper activity for B cells. NK activity in cord blood is also depressed compared to that in adults. Cord blood is a very rich source of hemopoietic progenitor cells. The spectrum of progenitors shows a predominance of early progenitor cells when compared with bone marrow. These cells provide an alternative source to adult bone marrow for stem cells to use for hemopoietic reconstitution and as targets in the treatment of hereditary deficiencies by gene therapy. These features make cord blood a unique research tool to investigate hemopoietic ontogeny and a unique clinical tool for transplantation.

show abstract

Section: Human Umbilical Cord Blood As a Source Of Hemopoietic Progenmentioning

confidence: 99%

Hemopoietic and Lymphoid Progenitor Cells in HumanUmbilical Cord Blood

Cicuttini

Boyd

1993

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Circulating blood cells are derived and replaced by a catenated system originating from hematopoietic stem and progenitor cells, recognized mostly by functional tests rather than by morphology (1)(2)(3)(4). The primary site of production of stem/progenitor cells in human adults is the bone marrow (1,2).…”

mentioning

confidence: 99%

Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.

Broxmeyer

Douglas

Hangoc

et al. 1989

Proc. Natl. Acad. Sci. U.S.A.

1,076

538

View full text Add to dashboard Cite

The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, the granulocyte-macrophage progenitor cell (CFU-GM) assay has been used with success as a valid indicator of engrafting capability. We examined greater than 100 collections of human umbilical cord blood for their content of nucleated cells and granulocyte-macrophage, erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, in many cases both before and after cryopreservation. First it was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition of anticoagulant for at least 3 days at 4 degrees C or 25 degrees C (room temperature), though not at 37 degrees C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy after transport of cord blood by overnight air freight carriage from a remote obstetrical service. Granulocyte-macrophage progenitor cells from cord blood so received responded normally to stimulation by purified recombinant preparations of granulocyte-macrophage, granulocyte, and macrophage colony-stimulating factors and interleukin 3. The salient finding, based on analysis of 101 cord blood collections, is that the numbers of progenitor cells present in the low-density (less than 1.077 gm/ml) fraction after Ficoll/Hypaque separation typically fell within the range that has been reported for successful engraftment by bone marrow cells. Another observation of practical importance is that procedures to remove erythrocytes or granulocytes prior to freezing, and washing of thawed cells before plating, entailed large losses of progenitor cells, the yield of unwashed progenitor cells from unfractionated cord blood being many times greater. The provisional inference is that human umbilical cord blood from a single individual is typically a sufficient source of cells for autologous (syngeneic) and for major histocompatibility complex-matched allogeneic hematopoietic reconstitution.

show abstract

“…Blood cells are derived from a small population of morphologically nonrecognizable cells in the bone marrow termed hematopoietic stem and progenitor cells (1,2). Myeloid blood cell production is regulated by networks of cell interactions involving production and release from accessory cells of molecules such as the hematopoietic colony-stimulating factors (CSFs): multi-CSF [also termed interleukin 3 (IL-3)], granulocyte-macrophage (GM)-CSF, granulocyte (G)-CSF, macrophage-CSF, as well as erythropoietin (Epo), and interleukins 1-6 (3)(4)(5)40).…”

mentioning

confidence: 99%

Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin.

Broxmeyer

Lü

Cooper

et al. 1988

Proc. Natl. Acad. Sci. U.S.A.

139

View full text Add to dashboard Cite

Activin and inhibin are biomolecules that, respectively, enhance and suppress the release of folliclestimulating hormone from pituitary cells in vitro. Purified recombinant human (rhu) activin A and inhibin A were assessed for their effects on colony formation in vitro by human multipotential (CFU-GEMM), erythroid (BFU-E), and granulocyte-macrophage (CFU-GM) progenitor cells. It was found that (i) rhu-activin A enhances colony formation by normal bone marrow erythroid and multipotential progenitor cells; (ii) purified rhu-inhibin A decreases activin, but not rhuinterleukin 3, rhu-granulocyte-macrophage colony-stimulating factor, or rhu-interleukin 4, enhancement of erythropoietin-stimulated colony formation by erythroid and multipotential progenitor cells; (iii) modulatory actions of rhu-activin and rhu-inhibin are mediated through monocytes and T lymphocytes within the marrow; (iv) actions are apparent in the absence or presence of serum; and (v) rhu-activin and rhu-inhibin have no effect on colony formation by granulocytemacrophage progenitor cells. This defines an indirect mode of action and a specificity for activin and inhibin on multipotential and erythroid progenitor cells.

show abstract

Characterization of hematopoietic stem and progenitor cells

Cited by 18 publications

References 70 publications

Hemopoietic and Lymphoid Progenitor Cells in HumanUmbilical Cord Blood

Hemopoietic and Lymphoid Progenitor Cells in HumanUmbilical Cord Blood

Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.

Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin.

Contact Info

Product

Resources

About